AccScience Publishing / GPD / Volume 2 / Issue 1 / DOI: 10.36922/gpd.v2i1.230

A novel signature identified by pyroptosis-related lncRNAs clusters predicts prognosis and tumor immune microenvironment for pediatric acute myeloid leukemia

Jie Lu1 Xinyu Chang1 Guowei Zheng1 Xiting Cao1 Zhenwei Wang1 Hao Zhu1 Shuaijie Gao1 Yuanlin Xi1*
Show Less
1 Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China
Submitted: 19 October 2022 | Accepted: 22 November 2022 | Published: 28 December 2022
© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Pyroptosis is a recently discovered programmed cell death that is involved in tumor formation, prognosis, and curative effect. Pyroptosis-related long non-coding ribonucleic acids (PR-lncRNAs) play key roles in tumorigenesis and tumor progression. However, the inherent relationship between PR-lncRNAs and the prognosis of pediatric acute myeloid leukemia (AML) remains unclear. For this reason, the association of PR-lncRNAs with the prognosis and tumor microenvironment features was analyzed using the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database. We classified three clusters based on PR-lncRNAs expressions and identified 841 differentially expressed PR-lncRNAs related to overall survival time. Seven key lncRNAs were then identified by least absolute shrinkage and selection operator (LASSO)-Cox and multivariate Cox. A signature based on these seven lncRNAs was also established, and the patients were separated into two groups according to their risk score. The high-risk group was characterized by poorer prognosis, lower expression of immune checkpoints, lower microsatellite instability or microsatellite stability (MSI-L/MSS), and lower drug sensitivity. The results demonstrated that PR-lncRNAs have a potential effect on the tumor immune microenvironment, clinicopathological features, and prognosis in pediatric AML. The nomogram and decision curve analysis suggested that the risk score is one of the most accurate of any other and provided a basis for the exploration of the immune microenvironment of the cell pyroptosis-associated subtypes in children with AML and the construction of a prognostic model with seven key PR-lncRNAs, which provides an approach to evaluate the prognosis of pediatric AML patients.

Pediatric acute myeloid leukemia
Pyroptosis; Long non-coding RNAs
Prognostic signature
Tumor immune microenvironment
Natural Science Foundation of Henan Province, China

Quessada J, Cuccuini W, Saultier P, et al., 2021, Cytogenetics of pediatric acute myeloid leukemia: A review of the current knowledge (in eng). Genes (Basel), 12(6): 924. 


Lejman M, Dziatkiewicz I, Jurek M, 2022, Straight to the point-the novel strategies to cure pediatric AML (in eng). Int J Mol Sci, 23(4): 1968.


Egan G, Chopra Y, Mourad S, et al., 2021, Treatment of acute myeloid leukemia in children: A practical perspective (in eng). Pediatr Blood Cancer, 68(7): e28979.


Kuwatsuka Y, Tomizawa D, Kihara R, et al., 2018, Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia (in eng). Int J Hematol, 107(2): 201–210.


Hsu SK, Li CY, Lin IL, et al., 2021, Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment (in eng). Theranostics, 11(18): 8813–8835.


Li L, Jiang M, Qi L, et al., 2021, Pyroptosis, a new bridge to tumor immunity (in eng). Cancer Sci, 112(10): 3979–3994.


Fang Y, Tian S, Pan Y, et al., 2020, Pyroptosis: A new frontier in cancer (in eng). Biomed Pharmacother, 121: 109595.


Xia X, Wang X, Cheng Z, et al., 2019, The role of pyroptosis in cancer: Pro-cancer or pro-“host”? (in eng). Cell Death Dis, 10(9): 650.


Johnson DC, Taabazuing CY, Okondo MC, et al., 2018, DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia (in eng). Nat Med, 24(8): 1151–1156.


Razmara M, Srinivasula SM, Wang L, et al., 2002, CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis (in eng). J Biol Chem, 277(16): 13952–13958.


Luo X, Zhang X, Gan L, et al., 2018, The outer membrane protein Tp92 of Treponema pallidum induces human mononuclear cell death and IL-8 secretion (in eng). J Cell Mol Med, 22(12): 6039–6054.


Bhan A, Soleimani M, Mandal SS, 2017, Long noncoding RNA and cancer: A new paradigm (in eng). Cancer Res, 77(15): 3965–3981.


Bridges MC, Daulagala AC, Kourtidis A, 2021, LNCcation: lncRNA localization and function (in eng). J Cell Biol, 220(2): e202009045.


He D, Zheng J, Hu J, et al., 2020, Long non-coding RNAs and pyroptosis (in eng). Clin Chim Acta, 504: 201–208. 


Weber CE, Kuo PC, 2012, The tumor microenvironment (in eng). Surg Oncol, 21(3): 172–177.


Newman AM, Liu CL, Green MR, et al., 2015, Robust enumeration of cell subsets from tissue expression profiles (in eng). Nat Methods, 12(5): 453–457. 


Ohaegbulam KC, Assal A, Lazar-Molnar E, et al., 2015, Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway (in eng). Trends Mol Med, 21(1): 24–33. 


Rowshanravan B, Halliday N, Sansom DM, 2018, CTLA-4: A moving target in immunotherapy (in eng). Blood, 131(1): 58–67. 


Maruhashi T, Sugiura D, Okazaki IM, et al., 2020, LAG-3: From molecular functions to clinical applications (in eng). J Immunother Cancer, 8(2): e001014. 


Zang K, Hui L, Wang M, et al., 2021, TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: A meta-analysis and bioinformatics validation (in eng). Front Oncol, 11: 579351.


Li L, Feng Q, Wang X, 2020, PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer (in eng). Comput Struct Biotechnol J, 18: 668–675.


Garzon R, Volinia S, Papaioannou D, et al., 2014, Expression and prognostic impact of lncRNAs in acute myeloid leukemia (in eng). Proc Natl Acad Sci U S A, 111(52): 18679– 18684.


Liu J, Geng R, Ni S, et al., 2022, Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC (in eng). Mol Ther Nucleic Acids, 27: 1036–1055.


Ping L, Zhang K, Ou X, et al., 2021, A novel pyroptosis-associated long non-coding RNA signature predicts prognosis and tumor immune microenvironment of patients with breast cancer (in eng). Front Cell Dev Biol, 9: 727183.


Guo M, Xiao ZD, Dai Z, et al., 2020, The landscape of long noncoding RNA-involved and tumor-specific fusions across various cancers (in eng). Nucleic Acids Res, 48(22): 12618–12631.


Lu Z, Tang F, Li Z, et al., 2022, Prognosis risk model based on pyroptosis-related lncRNAs for bladder cancer (in eng). Dis Markers, 2022: 7931393.


Aran D, Sirota M, Butte AJ, 2015, Systematic pan-cancer analysis of tumour purity (in eng). Nat Commun, 6: 8971. 


Abril-Rodriguez G, RibasA, 2017, SnapShot: Immune checkpoint inhibitors (in eng). Cancer Cell, 31(6): 848–848.e1. 


Vago L, Gojo I, 2020, Immune escape and immunotherapy of acute myeloid leukemia (in eng). J Clin Invest, 130(4): 1552–1564.


Jiang F, Wang XY, WangMY, et al., 2021, An immune checkpoint-related gene signature for predicting survival of pediatric acute myeloid leukemia (in eng). J Oncol, 2021: 5550116. 


He R, Wu S, Gao R, et al., 2021, Identification of a long noncoding RNA TRAF3IP2-AS1 as key regulator of IL-17 signaling through the SRSF10-IRF1-Act1 axis in autoimmune diseases (in eng). J Immunol, 206(10): 2353–2365.


Han Y, Ye A, Bi L, et al., 2014, Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia (in eng). Cancer Sci, 105(8): 933–942. 


Wróbel T, Mazur G, Jazwiec B, et al., 2003, Interleukin-17 in acute myeloid leukemia (in eng). J Cell Mol Med, 7(4): 472–474.


Li J, Zhang J, Tao S, et al., 2022, Prognostication of pancreatic cancer using the cancer genome atlas based ferroptosis-related long non-coding RNAs (in eng). Front Genet, 13: 838021.


Zhong F, Yao F, Cheng Y, et al., 2022, m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia (in eng). Sci Rep, 12(1): 1759.


Ni W, Mo H, Liu Y, et al., 2021, Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation (in eng). Mol Ther, 29(10): 2995–3010.


Chen C, Liang C, Wang S, et al., 2020, Expression patterns of immune checkpoints in acute myeloid leukemia (in eng). J Hematol Oncol, 13(1): 28.


Han L, Li Z, Jiang Y, et al., 2019, SNHG29 regulates miR- 223-3p/CTNND1 axis to promote glioblastoma progression via Wnt/β-catenin signaling pathway (in eng). Cancer Cell Int, 19: 345.


Li S, Wu D, Jia H, et al., 2020, Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC (in eng). Cell Death Dis, 11(8): 643.


Wu L, Liao W, Wang X, et al., 2021, Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis (in eng). Bioengineered, 12(2): 10302–10318. 


Bosman MC, Schepers H, Jaques J, et al., 2014, The TAK1- NF-κB axis as a therapeutic target for AML (in eng). Blood, 124(20): 3130–3140.


Fu T, Ji K, Jin L, et al., 2021, ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer (in eng). Gastric Cancer, 24(1): 45–59.


Zhou JG, Liang B, Liu JG, et al., 2021, Identification of 15 lncRNAs signature for predicting survival benefit of advanced melanoma patients treated with Anti-PD-1 monotherapy (in eng). Cells, 10(5): 977.


Rezaei M, Tan J, Zeng C, et al., 2021, TIM-3 in leukemia; Immune response and beyond (in eng). Front Oncol, 11: 753677.


Kikushige Y, Akashi K, 2012, TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia (in eng). Ann N Y Acad Sci, 1266: 118–123.


Du T, Gao J, Li P, et al., 2021, Pyroptosis, metabolism, and tumor immune microenvironment (in eng) Clin Transl Med, 11(8): e492. 


Park EG, Pyo SJ, Cui Y, et al., 2022, Tumor immune microenvironment lncRNAs (in eng). Brief Bioinform, 23(1): bbab504.

Conflict of interest
The authors declare no conflicts of interest.
Back to top
Gene & Protein in Disease, Electronic ISSN: 2811-003X Published by AccScience Publishing